Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation

September 2, 2013

A new article in the September 2013 issue of Thrombosis and Haemostasis strives to shed light on the optimal antithrombotic strategy in patients suffering from atrial fibrillation who undergo coronary stent implantation. This article shows that oral anticoagulation in patients with atrial fibrillation and high thromboembolic risk after stent implantation indeed lowers the risk of subsequent death, stroke and systemic thromboembolism. Yet when it comes to antithrombotic therapy, apparently guidelines are neglected.

The ideal antithrombotic strategy in patients with (AF) undergoing coronary is still subject to some debate. Nevertheless, patients at low risk of stroke in general receive dual , obviating the need for regular monitoring, while those at high risk theoretically would be better off with long-term oral anticoagulants. Triple therapy, consisting of oral anticoagulation, aspirin as well as at the initial phase, seemed the best option, but is associated with high bleeding rates. For patients with AF at low to intermediate risk of stroke, a dual antiplatelet therapy regime rather than triple therapy has also been suggested during the first months after placement of an intracoronary stent. In high-risk AF patients, oral anticoagulation is recommended to reduce the risk of stroke and . Recent guidelines have extended indications for oral anticoagulation to AF patients with one or more .

By gathering from a large cohort, Laurent Fauchier, MD, PhD, Professor of Cardiology, Trousseau University Hospital, Tours, France, and his colleagues wanted to find out whether oral anticoagulation at goes along with benefits in morbidity and mortality. They found that 23% of 417 investigated AF patients who underwent stent implantation received vitamin K antagonists when leaving the clinic. Oral anticoagulants were only used in a minority of patients in spite of their clinical benefit and dual antiplatelet therapy was the most common strategy in these patients (70%). The lack of oral anticoagulation at discharge, however, was independently associated with an increased risk of death, stroke and systemic thromboembolism, with older age, heart failure and a history of stroke. In short, oral anticoagulation lowered the risk of subsequent death or stroke in the afflicted. In turn, the authors concluded that oral anticoagulation should be systematically used in this patient population. He further noted that adherence to recent guidelines about management of oral anticoagulation is low in the afflicted. Thus the author urged that efforts be made to improve adherence to most recent guidelines in this patient subset, in particular since oral anticoagulation did not lead to a significantly higher risk of severe or major bleeding in this group of patients. He also pointed out that today new agents have become available which should facilitate decision-making as they are easier to use and at least as effective as vitamin K antagonists in reducing stroke rate and systemic embolism, but at the same time go along with lower major hemorrhage rates. These molecules may also be promising for AF patients with stent implantation.

In summary, the current paper demonstrates the necessity for a wider use of , as proposed in recent guidelines, in these patients because it was independently associated with a decreased risk of subsequent cardiovascular events. More needs to be done to improve outcomes in patients with AF undergoing coronary stenting.

Explore further: CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk

More information: Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation, Thromb Haemost 2013; 110: 560-568. nl5.sitepackage.de/link/2396_s … er.de/d0cc651ad99131

Related Stories

CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk

September 1, 2013
The CHADS2 stroke risk scores 0 or 1 assign more than one-third of patients in atrial fibrillation with stroke to low or intermediate risk not mandating oral anticoagulation, according to research presented at ESC Congress ...

GPs undertreat women with AF

September 1, 2013
General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that ...

Omission of aspirin from antiplatelet regimen: The WOEST study

August 28, 2012
Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and ...

Mass screening identifies untreated AF in 5% of 75-76 year olds

September 1, 2013
Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5-2% of the general population.1 Prevalence is estimated to ...

Female gender increases stroke risk in AF patients aged over 75 years by 20%

August 27, 2012
Female gender increases the risk of stroke in patients with atrial fibrillation (AF) aged >75 years by 20%, according to a study presented today at the ESC Congress 2012. The findings were presented by Anders Mikkelsen, from ...

Impact of AF on stroke risk eliminated with multiple risk factors

September 1, 2013
Patients with five or more risk factors have the same stroke risk as patients with atrial fibrillation, according to research presented at the ESC Congress today by Dr. Christine Benn Christiansen from Denmark. The study ...

Recommended for you

Gene therapy improved left ventricular and atrial function in heart failure by up to 25 percent

September 25, 2017
Heart function improved by up to 25 percent in a trial using gene therapy to reverse cardiac damage from congestive heart failure in a large animal model, Mount Sinai researchers report. This is the first study using a novel ...

Tension makes the heart grow stronger

September 25, 2017
By taking videos of a tiny beating zebrafish heart as it reconstructs its covering in a petri dish, scientists have captured unexpected dynamics of cells involved in tissue regeneration. They found that the depleted heart ...

Hospital mortality rates after heart attack differ by age

September 25, 2017
Outcomes for older patients hospitalized for a heart attack are often used as a measure of hospital quality for all patients. But a study led by Yale researchers shows that hospital mortality rates for older patients with ...

Laser device placed on the heart identifies insufficient oxygenation better than other measures

September 20, 2017
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital ...

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.